Zimmer Biomet Holdings, Inc. (ZBH)

Market Cap	25.30B
Revenue (ttm)	7.39B
Net Income (ttm)	1.02B
Shares Out	208.79M
EPS (ttm)	4.88
PE Ratio	24.87
Forward PE	14.91
Dividend	$0.96 (0.79%)
Ex-Dividend Date	Mar 27, 2024

Volume	978,732
Open	121.55
Previous Close	121.52
Day's Range	121.01 - 122.42
52-Week Range	102.00 - 149.25
Beta	1.02
Analysts	Buy
Price Target	141.00 (+16.37%)
Earnings Date	May 2, 2024

About ZBH

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open hear...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1927
• Employees: 18,000
• Stock Exchange: NYSE
• Ticker Symbol: ZBH

Financial Performance

In 2023, ZBH's revenue was $7.39 billion, an increase of 6.55% compared to the previous year's $6.94 billion. Earnings were $1.02 billion, an increase of 342.52%.

Analyst Forecast

According to 17 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price forecast is $141.0, which is an increase of 16.37% from the latest price.

Price Target

$141.0

(16.37% upside)

Analyst Consensus: Buy